{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:10:08Z","timestamp":1745917808964,"version":"3.40.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11060-025-04947-9","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:10:05Z","timestamp":1743840605000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular testing and targeting for solid tumors with CNS metastases"],"prefix":"10.1007","volume":"173","author":[{"given":"Kate E.","family":"Therkelsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan","family":"Roy-O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Stocksdale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"11","key":"4947_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney DN, Martin AM, Catalano PJ et al (2017) Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro-Oncol 19(11):1511\u20131521. https:\/\/doi.org\/10.1093\/neuonc\/nox077","journal-title":"Neuro-Oncol"},{"key":"4947_CR2","doi-asserted-by":"publisher","first-page":"662943","DOI":"10.3389\/fonc.2021.662943","volume":"11","author":"S Gupta","year":"2021","unstructured":"Gupta S, Dawood H, Giantini Larsen A et al (2021) Surgical and Peri-operative considerations for Brain metastases. Front Oncol 11:662943. https:\/\/doi.org\/10.3389\/fonc.2021.662943","journal-title":"Front Oncol"},{"key":"4947_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1748-717X-7-77","volume":"7","author":"AV Tallet","year":"2012","unstructured":"Tallet AV, Azria D, Barlesi F et al (2012) Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol Lond Engl 7:77. https:\/\/doi.org\/10.1186\/1748-717X-7-77","journal-title":"Radiat Oncol Lond Engl"},{"key":"4947_CR4","doi-asserted-by":"publisher","first-page":"847110","DOI":"10.3389\/fonc.2022.847110","volume":"12","author":"CI Ene","year":"2022","unstructured":"Ene CI, Ferguson SD (2022) Surgical Management of Brain Metastasis: challenges and nuances. Front Oncol 12:847110. https:\/\/doi.org\/10.3389\/fonc.2022.847110","journal-title":"Front Oncol"},{"issue":"3","key":"4947_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","volume":"17","author":"AG Nicholson","year":"2022","unstructured":"Nicholson AG, Tsao MS, Beasley MB et al (2022) The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol off Publ Int Assoc Study Lung Cancer 17(3):362\u2013387. https:\/\/doi.org\/10.1016\/j.jtho.2021.11.003","journal-title":"J Thorac Oncol off Publ Int Assoc Study Lung Cancer"},{"issue":"1","key":"4947_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40291-017-0308-6","volume":"22","author":"KA Hunter","year":"2018","unstructured":"Hunter KA, Socinski MA, Villaruz LC (2018) PD-L1 testing in guiding patient selection for PD-1\/PD-L1 inhibitor therapy in Lung Cancer. Mol Diagn Ther 22(1):1\u201310. https:\/\/doi.org\/10.1007\/s40291-017-0308-6","journal-title":"Mol Diagn Ther"},{"key":"4947_CR7","doi-asserted-by":"publisher","unstructured":"Placke JM, Kimmig M, Griewank K et al (2023) Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma \u2013 analysis of the DeCOG prospective multicenter cohort study ADOREG\/TRIM. eBioMedicine 96. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104774","DOI":"10.1016\/j.ebiom.2023.104774"},{"issue":"3","key":"4947_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/jcm11030828","volume":"11","author":"A Nepote","year":"2022","unstructured":"Nepote A, Avallone G, Ribero S et al (2022) Current controversies and challenges on BRAF V600K-Mutant cutaneous melanoma. J Clin Med 11(3):828. https:\/\/doi.org\/10.3390\/jcm11030828","journal-title":"J Clin Med"},{"issue":"9","key":"4947_CR9","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","volume":"15","author":"K Takeuchi","year":"2009","unstructured":"Takeuchi K, Choi YL, Togashi Y et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res off J Am Assoc Cancer Res 15(9):3143\u20133149. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3248","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res"},{"key":"4947_CR10","unstructured":"IHC Testing| Foundation Medicine. Accessed August 4 (2024) https:\/\/www.foundationmedicine.com\/info\/detail\/ihc-testing"},{"key":"4947_CR11","doi-asserted-by":"publisher","unstructured":"Dagogo-Jack I, Azzolli CG, Fintelmann F et al (2018) Clinical utility of Rapid EGFR genotyping in Advanced Lung Cancer. JCO Precis Oncol 21\u201313. https:\/\/doi.org\/10.1200\/PO.17.00299","DOI":"10.1200\/PO.17.00299"},{"issue":"1","key":"4947_CR12","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1038\/s41598-022-17394-7","volume":"12","author":"CI Shen","year":"2022","unstructured":"Shen CI, Chiang CL, Shiao TH et al (2022) Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer. Sci Rep 12(1):13566. https:\/\/doi.org\/10.1038\/s41598-022-17394-7","journal-title":"Sci Rep"},{"issue":"4","key":"4947_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jmoldx.2014.03.006","volume":"16","author":"HJ Abel","year":"2014","unstructured":"Abel HJ, Al-Kateb H, Cottrell CE et al (2014) Detection of gene rearrangements in targeted clinical next-generation sequencing. J Mol Diagn JMD 16(4):405\u2013417. https:\/\/doi.org\/10.1016\/j.jmoldx.2014.03.006","journal-title":"J Mol Diagn JMD"},{"issue":"1","key":"4947_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12920-021-00909-y","volume":"14","author":"C Heydt","year":"2021","unstructured":"Heydt C, W\u00f6lwer CB, Velazquez Camacho O et al (2021) Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. BMC Med Genomics 14(1):62. https:\/\/doi.org\/10.1186\/s12920-021-00909-y","journal-title":"BMC Med Genomics"},{"issue":"8","key":"4947_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/diagnostics10080521","volume":"10","author":"R Bruno","year":"2020","unstructured":"Bruno R, Fontanini G (2020) Next generation sequencing for Gene Fusion Analysis in Lung Cancer: A literature review. Diagnostics 10(8):521. https:\/\/doi.org\/10.3390\/diagnostics10080521","journal-title":"Diagnostics"},{"issue":"3","key":"4947_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"Yaeger R, Corcoran RB (2019) Targeting alterations in the RAF-MEK pathway. Cancer Discov 9(3):329\u2013341. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1321","journal-title":"Cancer Discov"},{"issue":"10","key":"4947_CR17","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Fisher MJ et al (2014) Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncol 16(10):1408\u20131416. https:\/\/doi.org\/10.1093\/neuonc\/nou059","journal-title":"Neuro-Oncol"},{"issue":"11","key":"4947_CR18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol off J Eur Soc Med Oncol 31(11):1491\u20131505. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.014","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"issue":"5","key":"4947_CR19","doi-asserted-by":"publisher","first-page":"100570","DOI":"10.1016\/j.esmoop.2022.100570","volume":"7","author":"S Schmid","year":"2022","unstructured":"Schmid S, Jochum W, Padberg B et al (2022) How to read a next-generation sequencing report-what oncologists need to know. ESMO Open 7(5):100570. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100570","journal-title":"ESMO Open"},{"issue":"3","key":"4947_CR20","doi-asserted-by":"publisher","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury CA, Creeden J, Yip WK et al (2022) Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE 17(3):e0264138. https:\/\/doi.org\/10.1371\/journal.pone.0264138","journal-title":"PLoS ONE"},{"issue":"10","key":"4947_CR21","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo C, Mack P, Scagliotti GV et al (2021) Liquid Biopsy for Advanced NSCLC: a Consensus Statement from the International Association for the study of Lung Cancer. J Thorac Oncol 16(10):1647\u20131662. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.017","journal-title":"J Thorac Oncol"},{"issue":"16suppl","key":"4947_CR22","doi-asserted-by":"publisher","first-page":"e21043","DOI":"10.1200\/JCO.2023.41.16_suppl.e21043","volume":"41","author":"H Bote","year":"2023","unstructured":"Bote H, Siringo M, Garc\u00eda-Lorenzo E et al (2023) Comparison between liquid biopsy and tissue NGS in two cohorts of advanced NSCLC. J Clin Oncol 41(16suppl):e21043\u2013e21043. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e21043","journal-title":"J Clin Oncol"},{"issue":"8","key":"4947_CR23","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3390\/cancers12082277","volume":"12","author":"HT Chan","year":"2020","unstructured":"Chan HT, Chin YM, Nakamura Y, Low SK (2020) Clonal hematopoiesis in Liquid Biopsy: from Biological noise to Valuable Clinical implications. Cancers 12(8):2277. https:\/\/doi.org\/10.3390\/cancers12082277","journal-title":"Cancers"},{"issue":"1","key":"4947_CR24","doi-asserted-by":"publisher","first-page":"10761","DOI":"10.1038\/s41598-021-89592-8","volume":"11","author":"J Garcia","year":"2021","unstructured":"Garcia J, Kamps-Hughes N, Geiguer F et al (2021) Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools. Sci Rep 11(1):10761. https:\/\/doi.org\/10.1038\/s41598-021-89592-8","journal-title":"Sci Rep"},{"issue":"15","key":"4947_CR25","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-19-1233","volume":"25","author":"CB Meador","year":"2019","unstructured":"Meador CB, Oxnard GR (2019) Effective Cancer genotyping-many means to one end. Clin Cancer Res off J Am Assoc Cancer Res 25(15):4583\u20134585. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1233","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res"},{"issue":"9","key":"4947_CR26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jtho.2017.05.022","volume":"12","author":"AG Sacher","year":"2017","unstructured":"Sacher AG, Komatsubara KM, Oxnard GR (2017) Application of plasma genotyping technologies in Non-small Cell Lung Cancer: a practical review. J Thorac Oncol off Publ Int Assoc Study Lung Cancer 12(9):1344\u20131356. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.022","journal-title":"J Thorac Oncol off Publ Int Assoc Study Lung Cancer"},{"issue":"12","key":"4947_CR27","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jtho.2021.07.008","volume":"16","author":"R Dziadziuszko","year":"2021","unstructured":"Dziadziuszko R, Mok T, Peters S et al (2021) Blood first assay screening trial (BFAST) in Treatment-Naive Advanced or metastatic NSCLC: initial results of the phase 2 ALK-Positive cohort. J Thorac Oncol 16(12):2040\u20132050. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.008","journal-title":"J Thorac Oncol"},{"issue":"9","key":"4947_CR28","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","volume":"28","author":"S Peters","year":"2022","unstructured":"Peters S, Dziadziuszko R, Morabito A et al (2022) Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med 28(9):1831\u20131839. https:\/\/doi.org\/10.1038\/s41591-022-01933-w","journal-title":"Nat Med"},{"issue":"7","key":"4947_CR29","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/s41591-024-03008-4","volume":"30","author":"S Peters","year":"2024","unstructured":"Peters S, Gadgeel SM, Mok T et al (2024) Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2\/3 BFAST trial. Nat Med 30(7):1923\u20131932. https:\/\/doi.org\/10.1038\/s41591-024-03008-4","journal-title":"Nat Med"},{"issue":"3","key":"4947_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11060-020-03555-z","volume":"148","author":"R Malani","year":"2020","unstructured":"Malani R, Fleisher M, Kumthekar P et al (2020) Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. J Neurooncol 148(3):599\u2013606. https:\/\/doi.org\/10.1007\/s11060-020-03555-z","journal-title":"J Neurooncol"},{"key":"4947_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.03.013","volume":"424","author":"G Marsavela","year":"2018","unstructured":"Marsavela G, Aya-Bonilla CA, Warkiani ME, Gray ES, Ziman M (2018) Melanoma circulating tumor cells: benefits and challenges required for clinical application. Cancer Lett 424:1\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2018.03.013","journal-title":"Cancer Lett"},{"key":"4947_CR32","doi-asserted-by":"crossref","unstructured":"Kumthekar P, Blouw B, Corkos P et al (2024) The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy. Front Oncol. Published online In","DOI":"10.3389\/fonc.2024.1402651"},{"key":"4947_CR33","doi-asserted-by":"publisher","first-page":"101688","DOI":"10.1016\/j.tranon.2023.101688","volume":"33","author":"RA Hickman","year":"2023","unstructured":"Hickman RA, Miller AM, Arcila ME (2023) Cerebrospinal fluid: a unique source of circulating tumor DNA with broad clinical applications. Transl Oncol 33:101688. https:\/\/doi.org\/10.1016\/j.tranon.2023.101688","journal-title":"Transl Oncol"},{"issue":"4","key":"4947_CR34","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/j.clbc.2021.11.002","volume":"22","author":"M Wooster","year":"2022","unstructured":"Wooster M, McGuinness JE, Fenn KM et al (2022) Diagnosis of Leptomeningeal Metastasis in Women with breast Cancer through identification of Tumor cells in Cerebrospinal Fluid using the CNSide\u2122 assay. Clin Breast Cancer 22(4):e457\u2013e462. https:\/\/doi.org\/10.1016\/j.clbc.2021.11.002","journal-title":"Clin Breast Cancer"},{"issue":"8","key":"4947_CR35","doi-asserted-by":"publisher","first-page":"e2120040","DOI":"10.1001\/jamanetworkopen.2021.20040","volume":"4","author":"MD White","year":"2021","unstructured":"White MD, Klein RH, Shaw B et al (2021) Detection of Leptomeningeal Disease using cell-free DNA from Cerebrospinal Fluid. JAMA Netw Open 4(8):e2120040. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.20040","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4947_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-021-00228-6","volume":"5","author":"Y Li","year":"2021","unstructured":"Li Y, Polyak D, Lamsam L et al (2021) Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases. Npj Precis Oncol 5(1):1\u20138. https:\/\/doi.org\/10.1038\/s41698-021-00228-6","journal-title":"Npj Precis Oncol"},{"issue":"10","key":"4947_CR37","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/diagnostics14101045","volume":"14","author":"P Zhong","year":"2024","unstructured":"Zhong P, Bai L, Hong M et al (2024) A Comprehensive Review on circulating cfRNA in plasma: implications for Disease diagnosis and Beyond. Diagn Basel Switz 14(10):1045. https:\/\/doi.org\/10.3390\/diagnostics14101045","journal-title":"Diagn Basel Switz"},{"issue":"1","key":"4947_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers14010017","volume":"14","author":"A Sharma","year":"2021","unstructured":"Sharma A, Singer L, Kumthekar P (2021) Updates on molecular targeted therapies for Intraparenchymal CNS Metastases. Cancers 14(1):17. https:\/\/doi.org\/10.3390\/cancers14010017","journal-title":"Cancers"},{"key":"4947_CR39","doi-asserted-by":"publisher","unstructured":"Naresh G, Malik PS, Khurana S et al (2021) Assessment of Brain Metastasis at diagnosis in non\u2013small-cell lung Cancer: a prospective Observational Study from North India. JCO Glob Oncol 7593\u2013601. https:\/\/doi.org\/10.1200\/GO.20.00629","DOI":"10.1200\/GO.20.00629"},{"issue":"1","key":"4947_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY (2012) Epidemiology of Brain metastases. Curr Oncol Rep 14(1):48\u201354. https:\/\/doi.org\/10.1007\/s11912-011-0203-y","journal-title":"Curr Oncol Rep"},{"issue":"Suppl 3","key":"4947_CR41","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.21037\/tlcr.2019.05.15","volume":"8","author":"M Nishino","year":"2019","unstructured":"Nishino M, Soejima K, Mitsudomi T (2019) Brain metastases in oncogene-driven non-small cell lung cancer. Transl Lung Cancer Res 8(Suppl 3):S298\u2013S307. https:\/\/doi.org\/10.21037\/tlcr.2019.05.15","journal-title":"Transl Lung Cancer Res"},{"issue":"12","key":"4947_CR42","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.jtho.2021.07.026","volume":"16","author":"H Yamaguchi","year":"2021","unstructured":"Yamaguchi H, Wakuda K, Fukuda M et al (2021) A phase II study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis from NSCLC: results for the T790M cohort of the OCEAN Study (LOGIK1603\/WJOG9116L). J Thorac Oncol off Publ Int Assoc Study Lung Cancer 16(12):2121\u20132132. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.026","journal-title":"J Thorac Oncol off Publ Int Assoc Study Lung Cancer"},{"issue":"12","key":"4947_CR43","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-21-1838","volume":"28","author":"LQM Chow","year":"2022","unstructured":"Chow LQM, Barlesi F, Bertino EM et al (2022) ASCEND-7: efficacy and safety of Ceritinib Treatment in patients with ALK-Positive non\u2013small cell Lung Cancer Metastatic to the brain and\/or Leptomeninges. Clin Cancer Res 28(12):2506\u20132516. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1838","journal-title":"Clin Cancer Res"},{"issue":"17suppl","key":"4947_CR44","doi-asserted-by":"publisher","first-page":"LBA9009","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9009","volume":"40","author":"JK Sabari","year":"2022","unstructured":"Sabari JK, Spira AI, Heist RS et al (2022) Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial. J Clin Oncol 40(17suppl):LBA9009\u2013LBA9009. https:\/\/doi.org\/10.1200\/JCO.2022.40.17_suppl.LBA9009","journal-title":"J Clin Oncol"},{"issue":"5","key":"4947_CR45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL et al (2022) Non\u2013small cell Lung Cancer, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 20(5):497\u2013530. https:\/\/doi.org\/10.6004\/jnccn.2022.0025","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"4947_CR46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","volume":"36","author":"GP Kalemkerian","year":"2018","unstructured":"Kalemkerian GP, Narula N, Kennedy EB et al (2018) Molecular Testing Guideline for the selection of patients with Lung Cancer for Treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists\/International Association for the Study of Lung Cancer\/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol off J Am Soc Clin Oncol 36(9):911\u2013919. https:\/\/doi.org\/10.1200\/JCO.2017.76.7293","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"4947_CR47","doi-asserted-by":"publisher","first-page":"e00156","DOI":"10.1016\/j.plabm.2020.e00156","volume":"20","author":"MR Al-Turkmani","year":"2020","unstructured":"Al-Turkmani MR, Suriawinata MA, Deharvengt SJ et al (2020) Rapid EGFR mutation testing in lung cancer tissue samples using a fully automated system and single-use cartridge. Pract Lab Med 20:e00156. https:\/\/doi.org\/10.1016\/j.plabm.2020.e00156","journal-title":"Pract Lab Med"},{"issue":"3","key":"4947_CR48","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.jtho.2021.01.112","volume":"16","author":"JM Bauml","year":"2021","unstructured":"Bauml JM, Viteri S, Minchom A et al (2021) FP07.12 underdiagnosis of EGFR exon 20 insertion mutation variants: estimates from NGS-based Real-World datasets. J Thorac Oncol 16(3):S208\u2013S209. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.112","journal-title":"J Thorac Oncol"},{"issue":"10","key":"4947_CR49","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","volume":"13","author":"JW Riess","year":"2018","unstructured":"Riess JW, Gandara DR, Frampton GM et al (2018) Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by Comprehensive genomic profiling of NSCLC. J Thorac Oncol off Publ Int Assoc Study Lung Cancer 13(10):1560\u20131568. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.019","journal-title":"J Thorac Oncol off Publ Int Assoc Study Lung Cancer"},{"issue":"36","key":"4947_CR50","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1200\/JCO.2006.07.0250","volume":"24","author":"Z Gabos","year":"2006","unstructured":"Gabos Z, Sinha R, Hanson J et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol off J Am Soc Clin Oncol 24(36):5658\u20135663. https:\/\/doi.org\/10.1200\/JCO.2006.07.0250","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"5","key":"4947_CR51","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/annonc\/mdp407","volume":"21","author":"A Niwi\u0144ska","year":"2010","unstructured":"Niwi\u0144ska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21(5):942\u2013948. https:\/\/doi.org\/10.1093\/annonc\/mdp407","journal-title":"Ann Oncol"},{"key":"4947_CR52","doi-asserted-by":"publisher","unstructured":"Zhang H, Finkelman BS, Ettel MG, Velez MJ, Turner BM, Hicks DG (2024) HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls. Histopathology Published Online March 5. https:\/\/doi.org\/10.1111\/his.15170","DOI":"10.1111\/his.15170"},{"key":"4947_CR53","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12935-022-02761-1","volume":"22","author":"L Morsberger","year":"2022","unstructured":"Morsberger L, Pallavajjala A, Long P et al (2022) HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry. Cancer Cell Int 22:350. https:\/\/doi.org\/10.1186\/s12935-022-02761-1","journal-title":"Cancer Cell Int"},{"issue":"9","key":"4947_CR54","doi-asserted-by":"publisher","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","volume":"147","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M et al (2023) Human epidermal growth factor receptor 2 testing in breast Cancer: American society of clinical oncology\u2013college of American pathologists Guideline Update. Arch Pathol Lab Med 147(9):993\u20131000. https:\/\/doi.org\/10.5858\/arpa.2023-0950-SA","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"4947_CR55","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/his.14728","volume":"81","author":"A Katayama","year":"2022","unstructured":"Katayama A, Starczynski J, Toss MS et al (2022) The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer. Histopathology 81(4):511\u2013519. https:\/\/doi.org\/10.1111\/his.14728","journal-title":"Histopathology"},{"issue":"2","key":"4947_CR56","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/ajcp\/aqy136","volume":"151","author":"IS Gibbons-Fideler","year":"2019","unstructured":"Gibbons-Fideler IS, Nitta H, Murillo A et al (2019) Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified breast cancers and their response to Anti-HER2 Neoadjuvant Chemotherapy. Am J Clin Pathol 151(2):176\u2013184. https:\/\/doi.org\/10.1093\/ajcp\/aqy136","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"4947_CR57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A et al (2020) Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive metastatic breast Cancer. N Engl J Med 382(7):597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609","journal-title":"N Engl J Med"},{"issue":"1","key":"4947_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer. N Engl J Med 387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"4947_CR59","unstructured":"FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer. FDA. Published online August 5, 2022. Accessed May 1 (2024) https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer"},{"issue":"5","key":"4947_CR60","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update. Arch Pathol Lab Med 144(5):545\u2013563. https:\/\/doi.org\/10.5858\/arpa.2019-0904-SA","journal-title":"Arch Pathol Lab Med"},{"issue":"9793","key":"4947_CR61","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet Lond Engl 378(9793):771\u2013784. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8","journal-title":"Lancet Lond Engl"},{"key":"4947_CR62","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fmolb.2020.00113","volume":"7","author":"I Vanni","year":"2020","unstructured":"Vanni I, Tanda ET, Spagnolo F, Andreotti V, Bruno W, Ghiorzo P (2020) The current state of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Front Mol Biosci 7:113. https:\/\/doi.org\/10.3389\/fmolb.2020.00113","journal-title":"Front Mol Biosci"},{"issue":"7666","key":"4947_CR63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao Z, Yaeger R, Rodrik-Outmezguine VS et al (2017) Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548(7666):234\u2013238. https:\/\/doi.org\/10.1038\/nature23291","journal-title":"Nature"},{"issue":"2","key":"4947_CR64","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jdermsci.2018.01.011","volume":"90","author":"Y Kiniwa","year":"2018","unstructured":"Kiniwa Y, Nakamura K, Mikoshiba A, Akiyama Y, Morimoto A, Okuyama R (2018) Diversity of circulating tumor cells in peripheral blood: detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis. J Dermatol Sci 90(2):211\u2013213. https:\/\/doi.org\/10.1016\/j.jdermsci.2018.01.011","journal-title":"J Dermatol Sci"},{"issue":"5","key":"4947_CR65","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1084\/jem.20181522","volume":"216","author":"S Garc\u00eda-Silva","year":"2019","unstructured":"Garc\u00eda-Silva S, Benito-Mart\u00edn A, S\u00e1nchez-Redondo S et al (2019) Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAFV600E mutation. J Exp Med 216(5):1061\u20131070. https:\/\/doi.org\/10.1084\/jem.20181522","journal-title":"J Exp Med"},{"issue":"90","key":"4947_CR66","doi-asserted-by":"publisher","first-page":"36238","DOI":"10.18632\/oncotarget.26343","volume":"9","author":"E Long-Mira","year":"2018","unstructured":"Long-Mira E, Ilie M, Chamorey E et al (2018) Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget 9(90):36238\u201336249. https:\/\/doi.org\/10.18632\/oncotarget.26343","journal-title":"Oncotarget"},{"issue":"11","key":"4947_CR67","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Carter SL, Santagata S et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5(11):1164\u20131177. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0369","journal-title":"Cancer Discov"},{"issue":"4","key":"4947_CR68","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/annonc\/mdn679","volume":"20","author":"CH Gow","year":"2009","unstructured":"Gow CH, Chang YL, Hsu YC et al (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol off J Eur Soc Med Oncol 20(4):696\u2013702. https:\/\/doi.org\/10.1093\/annonc\/mdn679","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"issue":"6","key":"4947_CR69","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/ijc.21940","volume":"119","author":"S Matsumoto","year":"2006","unstructured":"Matsumoto S, Takahashi K, Iwakawa R et al (2006) Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 119(6):1491\u20131494. https:\/\/doi.org\/10.1002\/ijc.21940","journal-title":"Int J Cancer"},{"issue":"3","key":"4947_CR70","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.lungcan.2013.01.019","volume":"80","author":"M Preusser","year":"2013","unstructured":"Preusser M, Berghoff AS, Ilhan-Mutlu A et al (2013) ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer Amst Neth 80(3):278\u2013283. https:\/\/doi.org\/10.1016\/j.lungcan.2013.01.019","journal-title":"Lung Cancer Amst Neth"},{"issue":"20","key":"4947_CR71","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1002\/cncr.32372","volume":"125","author":"H Wang","year":"2019","unstructured":"Wang H, Ou Q, Li D et al (2019) Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association study of thoracic oncology 1036). Cancer 125(20):3535\u20133544. https:\/\/doi.org\/10.1002\/cncr.32372","journal-title":"Cancer"},{"issue":"1","key":"4947_CR72","doi-asserted-by":"publisher","first-page":"vdab166","DOI":"10.1093\/noajnl\/vdab166","volume":"3","author":"R Tonse","year":"2021","unstructured":"Tonse R, Rubens M, Appel H et al (2021) Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. Neuro-Oncol Adv 3(1):vdab166. https:\/\/doi.org\/10.1093\/noajnl\/vdab166","journal-title":"Neuro-Oncol Adv"},{"issue":"5","key":"4947_CR73","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaoncol.2016.5630","volume":"3","author":"N Priedigkeit","year":"2017","unstructured":"Priedigkeit N, Hartmaier RJ, Chen Y et al (2017) Intrinsic subtype switching and acquired ERBB2\/HER2 amplifications and mutations in breast Cancer brain metastases. JAMA Oncol 3(5):666\u2013671. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5630","journal-title":"JAMA Oncol"},{"issue":"8","key":"4947_CR74","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/neuonc\/noaa013","volume":"22","author":"AFC Hulsbergen","year":"2020","unstructured":"Hulsbergen AFC, Claes A, Kavouridis VK et al (2020) Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro-Oncol 22(8):1173\u20131181. https:\/\/doi.org\/10.1093\/neuonc\/noaa013","journal-title":"Neuro-Oncol"},{"issue":"9","key":"4947_CR75","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/neuonc\/noaa025","volume":"22","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J et al (2020) Estrogen\/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncol 22(9):1359\u20131367. https:\/\/doi.org\/10.1093\/neuonc\/noaa025","journal-title":"Neuro-Oncol"},{"issue":"4","key":"4947_CR76","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1186\/bcr3244","volume":"14","author":"R Duchnowska","year":"2012","unstructured":"Duchnowska R, Dziadziuszko R, Trojanowski T et al (2012) Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res BCR 14(4):R119. https:\/\/doi.org\/10.1186\/bcr3244","journal-title":"Breast Cancer Res BCR"},{"issue":"11","key":"4947_CR77","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.5858\/2003-127-1451-NSIBCM","volume":"127","author":"KC Lear-Kaul","year":"2003","unstructured":"Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK, McGavran L, Singh M (2003) Her-2\/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 127(11):1451\u20131457. https:\/\/doi.org\/10.5858\/2003-127-1451-NSIBCM","journal-title":"Arch Pathol Lab Med"},{"issue":"20","key":"4947_CR78","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","volume":"30","author":"M Colombino","year":"2012","unstructured":"Colombino M, Capone M, Lissia A et al (2012) BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol off J Am Soc Clin Oncol 30(20):2522\u20132529. https:\/\/doi.org\/10.1200\/JCO.2011.41.2452","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"48","key":"4947_CR79","doi-asserted-by":"publisher","first-page":"e8404","DOI":"10.1097\/MD.0000000000008404","volume":"96","author":"EJ Hannan","year":"2017","unstructured":"Hannan EJ, O\u2019Leary DP, MacNally SP et al (2017) The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: the implications for BRAF inhibitor therapy. Med (Baltim) 96(48):e8404. https:\/\/doi.org\/10.1097\/MD.0000000000008404","journal-title":"Med (Baltim)"},{"key":"4947_CR80","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2017.05.015","volume":"81","author":"A Valachis","year":"2017","unstructured":"Valachis A, Ullenhag GJ (2017) Discrepancy in BRAF status among patients with metastatic malignant melanoma: a meta-analysis. Eur J Cancer Oxf Engl 1990 81:106\u2013115. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.015","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"4947_CR81","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","volume":"6","author":"L De Mattos-Arruda","year":"2015","unstructured":"De Mattos-Arruda L, Mayor R, Ng CKY et al (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839. https:\/\/doi.org\/10.1038\/ncomms9839","journal-title":"Nat Commun"},{"issue":"20","key":"4947_CR82","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/JCO.2016.66.6487","volume":"34","author":"EI Pentsova","year":"2016","unstructured":"Pentsova EI, Shah RH, Tang J et al (2016) Evaluating Cancer of the Central Nervous System through Next-Generation sequencing of Cerebrospinal Fluid. J Clin Oncol off J Am Soc Clin Oncol 34(20):2404\u20132415. https:\/\/doi.org\/10.1200\/JCO.2016.66.6487","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"8","key":"4947_CR83","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/neuonc\/noab294","volume":"24","author":"AK Mei\u00dfner","year":"2022","unstructured":"Mei\u00dfner AK, Gutsche R, Galldiks N et al (2022) Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases. Neuro-Oncol 24(8):1331\u20131340. https:\/\/doi.org\/10.1093\/neuonc\/noab294","journal-title":"Neuro-Oncol"},{"key":"4947_CR84","doi-asserted-by":"publisher","first-page":"878388","DOI":"10.3389\/fonc.2022.878388","volume":"12","author":"X Luo","year":"2022","unstructured":"Luo X, Xie H, Yang Y et al (2022) Radiomic signatures for Predicting receptor status in breast Cancer brain metastases. Front Oncol 12:878388. https:\/\/doi.org\/10.3389\/fonc.2022.878388","journal-title":"Front Oncol"},{"key":"4947_CR85","doi-asserted-by":"publisher","first-page":"931812","DOI":"10.3389\/fonc.2022.931812","volume":"12","author":"L Zheng","year":"2022","unstructured":"Zheng L, Xie H, Luo X et al (2022) Radiomic signatures for Predicting EGFR Mutation Status in Lung Cancer Brain metastases. Front Oncol 12:931812. https:\/\/doi.org\/10.3389\/fonc.2022.931812","journal-title":"Front Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-04947-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T08:30:09Z","timestamp":1745915409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-04947-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["4947"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-04947-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}